观察！《妈妈！》斩获澳涞坞五大洲电影节金莉花奖，杨荔钠获华语最佳导演殊荣

《妈妈！》斩获澳涞坞五大洲电影节金莉花奖，杨荔钠获华语最佳导演殊荣

澳门，2023年4月4日 - 由澳涞坞制片人协会主办的第二届澳涞坞五大洲电影节金莉花奖颁奖典礼昨晚在澳门隆重举行。来自全球各地的优秀电影人齐聚一堂，共同见证了这一电影盛事的荣耀时刻。

中国电影《妈妈！》在本次评选中脱颖而出，荣获华语最佳影片奖。该片由杨荔钠执导，讲述了一对老年母女在面对阿尔兹海默症带来的困境时，相互扶持、坚守爱与希望的故事。影片细腻感人的剧情和出色的表演，获得了评委的一致认可。

导演杨荔钠凭借《妈妈！》的出色执导，荣获华语最佳导演奖。杨荔钠是一位经验丰富的电影人，曾执导过多部备受好评的电影作品。此次获奖是对她多年来艺术追求的不懈肯定。

在其他奖项中，陈宝国凭借在电影《海的尽头是草原》中的精彩表演，获得华语最佳男演员奖；刘浩存凭借在电影《四海》中的出色表现，获得华语最佳女演员奖。

澳涞坞五大洲电影节金莉花奖是世界电影产业大会的重要组成部分，旨在表彰全球范围内优秀的电影作品和电影人。本届电影节的成功举办，为促进世界电影文化交流、推动电影产业发展做出了积极贡献。

以下是对获奖影片和导演的进一步介绍：

• 《妈妈！》：该片由吴彦姝、奚美娟主演，讲述了一位退休工程师女儿患上阿尔兹海默症后，年迈的母亲独自照顾女儿的感人故事。影片以细腻的笔触刻画了母女之间深厚的情感，引发了观众对老年人关怀和家庭伦理的思考。
• 杨荔钠：杨荔钠是一位中国电影导演、编剧和制片人。她曾执导过多部备受好评的电影作品，包括《春梦》、《春潮》和《妈妈！》。杨荔钠的电影作品以女性视角切入，关注现实生活中的女性困境，具有鲜明的个人风格。

获奖名单：

• 全球最佳影片：《西线无战事》
• 全球最佳男主角：丹尼尔·布鲁赫（《西线无战事》）
• 全球最佳女主角：格拉西娅·菲利波维奇（《海鳝》）
• 全球最佳导演：卢卡·瓜达尼诺（《骨及所有》）
• 华语最佳影片：《妈妈！》
• 华语最佳导演：杨荔钠（《妈妈！》）
• 华语最佳男演员：陈宝国（《海的尽头是草原》）
• 华语最佳女演员：刘浩存（《四海》）

澳涞坞五大洲电影节

澳涞坞五大洲电影节是由澳涞坞制片人协会主办的一个全球性国际电影节，创办于2022年，旨在表彰全世界对电影艺术发展作出积极探索和创新的优秀电影作品和电影人。电影节的评选范围涵盖全球各个国家和地区，并设置了全球最佳影片、全球最佳导演、全球最佳男主角、全球最佳女主角等多个奖项。

结语

第二届澳涞坞五大洲电影节金莉花奖的颁发，为全球电影爱好者奉献了一场精彩的视听盛宴。同时也为促进世界电影文化交流、推动电影产业发展做出了积极贡献。相信未来，澳涞坞五大洲电影节将继续坚持其国际化、专业化的办节理念，为观众带来更多优秀电影作品，为世界电影事业发展注入新的活力。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.